Investigating gene expression profile of non-small cell lung cancer

  • Tõnu Vooder
  • Andres Metspalu
Mini Review


Lung cancer is mainly a lifestyle-associated disease with poor prognosis and the lowest five year survival rate of all types of cancer. Lung cancers are divided into two main groups: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Surgical treatment is generally indicated in cases of early stage NSCLC, and those patients treated with radical and aggressive surgery have a somewhat better survival rate. The main problems with lung cancer treatment are due to late diagnosis, rapidly developing drug resistance and side effects of the treatment that are experienced by almost all patients. The next step for distinguishing histologically complicated lung cancers and determining optimal treatment strategies is gene expression analysis. Supported by gene expression data, it is possible to prognosticate the course of the disease.


Lung cancer Non-small cell lung cancer Gene expression Microchip Molecular markers 


  1. [1]
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul–Aug;59(4):225–249PubMedCrossRefGoogle Scholar
  2. [2]
    Levi F, Lucchini F, Negri E, La Vecchia C. Trends in mortality from major cancers in the European Union, including acceding countries, in 2004. Cancer. 2004 Dec 15;101(12):2843–2850PubMedCrossRefGoogle Scholar
  3. [3]
    Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007 Jan;12(1):20–37PubMedCrossRefGoogle Scholar
  4. [4]
    Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer. 1999 Nov 1;86(9):1867–1876PubMedCrossRefGoogle Scholar
  5. [5]
    Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: looking to the future. J Clin Oncol. 2005 May 10;23(14):3175–3185PubMedCrossRefGoogle Scholar
  6. [6]
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J. 2001 Dec;18(6):1059–1068PubMedCrossRefGoogle Scholar
  7. [7]
    Anbazhagan R, Tihan T, Bornman DM, Johnston JC, Saltz JH, Weigering A, et al. Classification of small cell lung cancer and pulmonary carcinoid by gene expression profiles. Cancer Res. 1999 Oct 15;59(20):5119–5122PubMedGoogle Scholar
  8. [8]
    Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest. 1994 Dec;106(6 Suppl):367S–371SPubMedCrossRefGoogle Scholar
  9. [9]
    Okubo C, Minami Y, Tanaka R, Uchihara T, Anami Y, Furuya S, et al. Analysis of differentially expressed genes in neuroendocrine carcinomas of the lung. J Thorac Oncol. 2006 Oct;1(8):780–786PubMedCrossRefGoogle Scholar
  10. [10]
    Wistuba, II, Berry J, Behrens C, Maitra A, Shivapurkar N, Milchgrub S, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000 Jul;6(7):2604–2610PubMedGoogle Scholar
  11. [11]
    Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet. 2007 Aug;8(8):601–609PubMedCrossRefGoogle Scholar
  12. [12]
    Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, et al. Expression of gemcitabine- and cisplatin-related genes in nonsmall-cell lung cancer. The pharmacogenomics journal. 2009 Nov 10Google Scholar
  13. [13]
    Raponi M, Zhang Y, Yu J, Chen G, Lee G, Taylor JM, et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res. 2006 Aug 1;66(15):7466–7472PubMedCrossRefGoogle Scholar
  14. [14]
    Gray J, Simon G, Bepler G. Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Rev Anticancer Ther. 2007 Apr;7(4):545–549PubMedCrossRefGoogle Scholar
  15. [15]
    Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000 Feb 3;403(6769):503–511PubMedCrossRefGoogle Scholar
  16. [16]
    Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790–13795PubMedCrossRefGoogle Scholar
  17. [17]
    van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002 Dec 19;347(25):1999–2009PubMedCrossRefGoogle Scholar
  18. [18]
    Cooper D. The Molecular Genetics of Lung Cancer. Heidelberg: Springer-Verlag 2005Google Scholar
  19. [19]
    Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest. 2005 Jul;128(1):370–381PubMedCrossRefGoogle Scholar
  20. [20]
    Dennis JL, Vass JK, Wit EC, Keith WN, Oien KA. Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. Cancer Res. 2002 Nov 1;62(21):5999–6005PubMedGoogle Scholar
  21. [21]
    Giordano TJ, Shedden KA, Schwartz DR, Kuick R, Taylor JM, Lee N, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol. 2001 Oct;159(4):1231–1238PubMedCrossRefGoogle Scholar
  22. [22]
    Vooder T, Valk K, Kolde R, Roosipuu R, Vilo J, Metspalu A. Gene Expression-Based Approaches in Differentiation of Metastases and Second Primary Tumour. Case Rep Oncol.3(2):255–261Google Scholar
  23. [23]
    Bridgewater J, van Laar R, Floore A, Van TVL. Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary. British journal of cancer. 2008 Apr 22;98(8):1425–1430PubMedCrossRefGoogle Scholar
  24. [24]
    Wigle DA, Jurisica I, Radulovich N, Pintilie M, Rossant J, Liu N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002 Jun 1;62(11):3005–3008PubMedGoogle Scholar
  25. [25]
    Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002 Aug; 8(8):816–824PubMedGoogle Scholar
  26. [26]
    Bianchi F, Nuciforo P, Vecchi M, Bernard L, Tizzoni L, Marchetti A, et al. Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. J Clin Invest. 2007 Oct 18Google Scholar
  27. [27]
    Lu Y, Lemon W, Liu PY, Yi Y, Morrison C, Yang P, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. PLoS Med. 2006 Dec;3(12):e467PubMedCrossRefGoogle Scholar
  28. [28]
    Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007 Feb 22;356(8):800–808PubMedCrossRefGoogle Scholar
  29. [29]
    Tomida S, Koshikawa K, Yatabe Y, Harano T, Ogura N, Mitsudomi T, et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. Oncogene. 2004 Jul 8;23(31):5360–5370PubMedCrossRefGoogle Scholar
  30. [30]
    Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007 Jan 4;356(1):11–20PubMedCrossRefGoogle Scholar
  31. [31]
    Lau SK, Boutros PC, Pintilie M, Blackhall FH, Zhu CQ, Strumpf D, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 2007 Dec 10;25(35):5562–5569PubMedCrossRefGoogle Scholar
  32. [32]
    Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003 Oct;3(10):733–744PubMedCrossRefGoogle Scholar
  33. [33]
    Powell CA, Spira A, Derti A, DeLisi C, Liu G, Borczuk A, et al. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am J Respir Cell Mol Biol. 2003 Aug;29(2):157–162PubMedCrossRefGoogle Scholar
  34. [34]
    Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):29S–55SPubMedCrossRefGoogle Scholar
  35. [35]
    Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006 May 10;24(14):2158–2163PubMedCrossRefGoogle Scholar
  36. [36]
    Cerfolio RJ, Bryant AS, Scott E, Sharma M, Robert F, Spencer SA, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest. 2006 Dec;130(6):1796–1802PubMedCrossRefGoogle Scholar
  37. [37]
    Planchard D, Loriot Y, Goubar A, Commo F, Soria JC. Differential expression of biomarkers in men and women. Seminars in oncology. 2009 Dec;36(6):553–565PubMedCrossRefGoogle Scholar
  38. [38]
    Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst. 2000 Nov 1;92(21):1764–1772PubMedCrossRefGoogle Scholar
  39. [39]
    Wei Z, Lifen J, Jiliang H, Jianlin L, Baohong W, Hongping D. Detecting DNA repair capacity of peripheral lymphocytes from cancer patients with UVC challenge test and bleomycin challenge test. Mutagenesis. 2005 Jul;20(4):271–277PubMedCrossRefGoogle Scholar
  40. [40]
    Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006 Sep 7;355(10):983–991PubMedCrossRefGoogle Scholar
  41. [41]
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinumbased chemotherapy. Clin Cancer Res. 2004 Aug 1;10(15):4939–4943PubMedCrossRefGoogle Scholar

Copyright information

© © Versita Warsaw and Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.medical faculty, Lung ClinicTartu UniversityTartuEstonia
  2. 2.Institute of Molecular and Cell Biology, Department of BiotechnologyTartu UniversityTartuEstonia
  3. 3.Estonian Genome FoundationTartuEstonia

Personalised recommendations